Skip to main content
. 2024 Jun 20;12(6):1374. doi: 10.3390/biomedicines12061374

Table 3.

Performance of the MCR score as a predictor of MACEs using 503 patients with peripheral artery disease.

Events Low Risk
(N = 100)
Moderate Risk
(N = 115)
High Risk
(N = 140)
Very High Risk
(N = 148)
Major adverse cardiovascular events (MACEs)
#MACEs (%) 3 (3) 13 (11.30) 16 (11.43) 17 (11.49)
Crude HR (95% CI) 1 3.52 (1.00–12.12) 4.18 (1.22–14.36) 5.08 (1.49–17.36)
p value 0.048 * 0.023 * 0.009 *
Multivariate adjusted HR (95% CI) 1 2.57 (0.55–9.31) 3.51 (0.78–15.86) 4.67 (1.03–21.09)
p value 0.231 0.102 0.045 *
Major adverse limb events (MALEs)
# MALEs (%) 31 (31) 49 (42.60) 63 (45) 50 (33.78)
Crude HR (95% CI) 1 1.33 (0.85–2.09) 1.55 (1.01–2.38) 1.21 (0.77–1.89)
p value 0.213 0.046 * 0.398
Multivariate adjusted HR (95% CI) 1 1.29 (0.81–2.33) 1.66 (1.04–3.2) 1.34 (0.79–2.94)
p value 0.30 0.039 * 0.249
Major adverse limb and cardiac events
(MALEs + MACEs)
#MALEs + MACEs (%) 34 (34) 57 (49.57) 70 (50) 63 (42.57)
Crude HR (95% CI) 1 1.37 (0.89–2.09) 1.58 (1.05–2.37) 1.41 (0.93–2.14)
p value 0.145 0.029 * 0.107
Multivariate adjusted HR (95%CI) 1 1.35 (0.85–2.13) 1.6 (1.01–2.53) 1.46 (0.92–2.30)
p value 0.204 0.045 * 0.108

Multivariate model adjusted by factors that were found significant in Tables S2 and S3 for MACEs, MALEs, and MALEs + MACEs. Multivariate models were adjusted by coronary artery disease, coronary artery bypass graft (CABG), chronic obstructive pulmonary disorder, myocardial infarction, chronic kidney disease, hemodialysis, peritoneal dialysis, creatinine, and atrial fibrillation. *: significant with p-value < 0.05.